NF2 and cancer: In some instances of cancer, it has been shown that inactivity of upstream Hippo pathway members (e.g., through mutations in NF2/MERLIN, LATS1, LATS2 or SAV1) can lead to over-activity of YAP/TAZ, which can lead to tumour initiation [85,86,87,88].